Asghari Alashti Fariborz, Goliaei Bahram, Minuchehr Zarrin
Institute of Biochemistry and Biophysics (IBB), University of Tehran Tehran, Iran.
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Department of Laboratory Medicine and Pathobiology, University of Toronto Ontario, Canada.
Am J Cancer Res. 2022 Jan 15;12(1):371-380. eCollection 2022.
Early detection of colorectal cancer (CRC) increases the chances of survival and reduces the therapeutic problems and costs of treatment. Since molecular biomarkers can help us diagnose colorectal cancer early, we need to identify novel gene for predicting the early stages of tumorigenesis. Here, we integrated five independent CRC gene expression datasets derived from expression profiling by array comparing CRC with normal samples in: GSE21510, GSE4107, GSE25071, GSE15781 dataset, and GSE8671 dataset, including 64 samples from 32 patients comparing 32 colonic normal mucosa with 32 colorectal adenoma. To detect genes that expressed differentially in experimental circumstances of these datasets, we used web tool of GEO2R to compare groups of samples in the GEO data series. Furthermore, we constructed the protein-protein interactions network by STRING database for mostly downregulated genes and the expression of their members in PPI network were studied into five datasets separately. Also, the level of expression of selected biomarker genes in different stages of CRC compared to normal was studied. Our data revealed 17 common downregulated genes (average fold change (FC) in five tests ≥6) in CRC in comparison with normal (Test 1 to Test 4) and in adenoma compared with normal (Test 5). Studying of gene expression of PPI network members of these downregulated genes led to identifying of CLCA1, SELENBP1, CWC25, ACOT11, GUCY2C and ALDH1A1 as suppressor genes and PTGS2, PROCR, MOCS3 and NFS1 as oncogenes which respectively downregulated and upregulated in CRC. Since decreasing of gene expression was seen in CRC comparing with normal and due to no different expression seen for these 10 genes in adenoma, they, especially CLCA1 and SELENBP1, could be considered as biomarkers for early detection of CRC. Before using these signature genes in the clinic; however, further validations are required.
早期检测结直肠癌(CRC)可提高生存率,减少治疗问题和治疗成本。由于分子生物标志物有助于我们早期诊断结直肠癌,因此我们需要鉴定预测肿瘤发生早期阶段的新基因。在此,我们整合了五个独立的CRC基因表达数据集,这些数据集来自通过阵列进行的表达谱分析,将CRC与正常样本在以下数据集中进行比较:GSE21510、GSE4107、GSE25071、GSE15781数据集和GSE8671数据集,包括来自32名患者的64个样本,将32份结肠正常黏膜与32份结肠直肠腺瘤进行比较。为了检测在这些数据集的实验情况下差异表达的基因,我们使用GEO2R网络工具比较GEO数据系列中的样本组。此外,我们通过STRING数据库构建了主要下调基因的蛋白质-蛋白质相互作用网络,并分别在五个数据集中研究了它们在PPI网络中的成员表达。此外,还研究了与正常相比,所选生物标志物基因在CRC不同阶段的表达水平。我们的数据显示,与正常相比(测试1至测试4)以及与腺瘤相比(测试5),CRC中有17个共同下调基因(五次测试中的平均倍数变化(FC)≥6)。对这些下调基因的PPI网络成员的基因表达进行研究,导致鉴定出CLCA1、SELENBP1、CWC25、ACOT11、GUCY2C和ALDH1A1为抑制基因,PTGS2、PROCR、MOCS3和NFS1为癌基因,它们在CRC中分别下调和上调。由于与正常相比,CRC中基因表达下降,并且由于这10个基因在腺瘤中未观察到不同表达,因此它们,尤其是CLCA1和SELENBP1,可被视为早期检测CRC的生物标志物。然而,在临床使用这些特征基因之前,还需要进一步验证。